Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors D.S. Goldfarb, P.A. MacDonald, B. Hunt, L. Gunawardhana ........................................ 1385


Long-term Therapeutic Response to Milnacipran Treatment for FM. A European 1-Year Extension Study Following a 3-Month Study J.C. Branco, P. Cherin, A. Montagne, A. Bouroubi, on behalf of the Multinational Coordinator Study Group. . 1403


Pediatric Rheumatology

Heterotopic Ossification of the TMJ in JIA S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace ................................. 1423

MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Ku, J-L. Huang ........................................ 1429

Safety and Efficacy of Rituximab in Severe Juvenile DM: Results from 9 Patients from the French Autoimmunity and Safety and Efficacy of Rituximab in Severe Juvenile DM: Results from 9 Patients from the French Autoimmunity and Rituximab Registry B. Bader-Meunier, H. Decaluwe, C. Barnerias, et al. for the Club Rhumatismes et Inflammation .................................. 1436

Development of IBD in Patients with JIA Treated with Etanercept T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al. ................................ 1441

Images in Rheumatology

Fluorescence Optical Imaging of Juvenile Arthritis S.G. Werner, H-E. Langer, G. Horneff ................................................................. 1447

OMERACT 10

10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010

Introduction ............................................................................. 1448

Disease-specific Outcomes


Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities N. Dalbeth, F.M. McQueen, J.A. Singh, et al. ...................... 1458

Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology? L.K. Stamp, P.P. Khanna, N. Dalbeth, et al. ........................................ 1462


The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis P.A. Merkel, S.Z. Aydin, M. Boers, et al. ........................................ 1480

Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update P.J. Mease, D.J. Clauw, R. Christensen, et al. and the OMERACT Fibromyalgia Working Group ................................................... 1487

Development of a Disease Severity and Responder Index for PsA — Report of the OMERACT 10 PsA SIG L.C. Coates, A. Mumtaz, P.S. Helliwell, et al. .................................. 1496

Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde ................................................... 1502


Developing Disease Activity and Response Criteria in CTD-related ILD L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group. .................................................. 1514

Correspondence

Where in the World is Oral Triamcinolone? L. Roger ........................................ 1519

Reply R. Alten ................................................................. 1519

Lupus Related Longitudinal Myelitis D.M. Wingerchuk, B.G. Wemshenker ................................................................. 1520

Reply P. Zotos ................................................................. 1521


Who Discovered the ESR? A. Grzybowski, J.J. Sak ........................................ 1521

Reply E.L. Matteson, C.S. Crowson ........................................ 1523

Letters


Acute Presentation of Tophaceous Myelopathy E. Levin, K. Hurth, R. Joshi, R. Brasington ................................................................. 1525

AS Refractory to TNF Blockade Responds to Tocilizumab J-D. Cohen, R. Fereira, C. Jorgensen ................................................................. 1527

Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis M. Uh, I.A. McCormick, J.T. Kelsall ................................................................. 1528

Primary Aldosteronism Simulating Polymyositis Y-C. Tang, S-K. Wang, W-L. Yuan ................................................................. 1529

Corrections

Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial J.A. Singh, M.L. Mahowald, S. Noorbalaouchi ................................................................. 1534


Meetings in Rheumatology